| Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) (NCT02859038) | Shanghai Gynecologic Oncology Group | 2016-08-01 |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT02489006) | University Health Network, Toronto | 2016-07-19 |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers (NCT02725489) | Mary Crowley Medical Research Center | 2016-06-03 |
| A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers (NCT02728830) | AA Secord | 2016-06-01 |
| A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers (NCT02824328) | Duke University | 2016-06-01 |
| Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (NCT02759588) | Genelux Corporation | 2016-05-01 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (NCT02606305) | ImmunoGen, Inc. | 2016-03-02 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (NCT02631876) | ImmunoGen, Inc. | 2016-03-02 |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer (NCT02571725) | New Mexico Cancer Research Alliance | 2016-02-23 |
| LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer (NCT02668913) | Geoff Hall | 2016-02-01 |
| Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer (NCT02534922) | Oncolix, Inc. | 2016-02-01 |
| A Study of Long-Term Responders on Olaparib (NCT02489058) | University Health Network, Toronto | 2016-02-01 |
| Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (NCT02433626) | Critical Outcome Technologies Inc. | 2015-12-01 |
| Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients (NCT02470299) | New Mexico Cancer Research Alliance | 2015-10-29 |
| Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer (NCT02480374) | Imunon | 2015-09-01 |
| Total/Subtotal Colectomy in Ovarian Cancer (NCT02595021) | Shanghai Gynecologic Oncology Group | 2015-07-01 |
| p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (NCT02435186) | Shenzhen SiBiono GeneTech Co.,Ltd | 2015-06-01 |
| Autologous OC-L Vaccine and Ovarian Cancer (NCT02452775) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT02278783) | University of Utah | 2015-03-01 |
| Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission (NCT02324439) | Southern Illinois University | 2015-03-01 |
| "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01883297) | University Health Network, Toronto | 2015-01-01 |
| Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors (NCT02262455) | Santa Maria Biotherapeutics | 2014-10-01 |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (NCT01610869) | University College, London | 2014-08-01 |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer (NCT02012192) | Medical University Innsbruck | 2014-07-04 |
| Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT02121990) | Memorial Sloan Kettering Cancer Center | 2014-04-21 |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (NCT01968213) | pharmaand GmbH | 2014-04-07 |
| HOT: HIPEC in Ovarian Cancer as Initial Treatment (NCT02124421) | Mercy Medical Center | 2014-04-01 |
| Tivozanib As Maintenance Therapy In GYN (NCT01972516) | Dana-Farber Cancer Institute | 2013-11-01 |
| The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (NCT01556841) | University College, London | 2013-11-01 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (NCT01891344) | pharmaand GmbH | 2013-10-30 |
| PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer (NCT01899599) | Glycotope GmbH | 2013-09-01 |
| Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer (NCT03332576) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2013-08-23 |
| BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (NCT01669798) | AA Secord | 2013-02-01 |
| Accelerating Gastrointestinal Recovery (NCT01704651) | Jamie N. Bakkum-Gamez | 2013-01-01 |
| 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (NCT01766622) | National Institutes of Health Clinical Center (CC) | 2012-11-30 |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01666444) | Celgene | 2012-10-31 |
| Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer (NCT01744821) | Northwestern University | 2012-10-01 |
| Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer (NCT03480750) | National Cheng-Kung University Hospital | 2012-09-01 |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer (NCT01610206) | Linda R Duska | 2012-09-01 |
| Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer (NCT01661868) | Dana-Farber Cancer Institute | 2012-08-01 |
| Interactive Educational Website for Women With Ovarian Cancer & Caregivers (NCT01626014) | University of Minnesota | 2012-08-01 |
| A Study LY2228820 for Recurrent Ovarian Cancer (NCT01663857) | Eli Lilly and Company | 2012-07-01 |
| Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (NCT01402271) | European Organisation for Research and Treatment of Cancer - EORTC | 2012-07-01 |
| Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer (NCT01591772) | Memorial Sloan Kettering Cancer Center | 2012-04-24 |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01670799) | New Mexico Cancer Research Alliance | 2012-03-01 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer (NCT01493505) | Amgen | 2012-01-01 |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer (NCT01416038) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2011-12-01 |
| Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer (NCT01471483) | Memorial Sloan Kettering Cancer Center | 2011-11-08 |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) (NCT01482715) | pharmaand GmbH | 2011-11-01 |
| A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers (NCT01447706) | Merrimack Pharmaceuticals | 2011-10-01 |
| A Survivorship Care Plan for Gynaecological Cancer Patients (NCT01582906) | Royal Marsden NHS Foundation Trust | 2011-08-01 |
| Validation of a Nutrition Screening Tool (NCT01851928) | Royal Marsden NHS Foundation Trust | 2011-07-01 |
| Search for Predictors of Therapeutic Response in Ovarian Carcinoma (NCT01391351) | Centre Francois Baclesse | 2011-06-01 |
| Pelvic Floor Disorders in Survivors of Gynecologic Malignancies (NCT01370122) | Abramson Cancer Center at Penn Medicine | 2011-05-01 |
| Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer (NCT01220154) | David O'Malley | 2011-04-28 |
| AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) (NCT01281254) | Amgen | 2011-04-18 |
| A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01312389) | Abramson Cancer Center at Penn Medicine | 2011-04-01 |
| Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT01137071) | Recepta Biopharma | 2011-04-01 |
| Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (NCT01196741) | University College, London | 2011-03-01 |
| Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer (NCT01312376) | Abramson Cancer Center at Penn Medicine | 2011-03-01 |
| Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers (NCT01237067) | National Cancer Institute (NCI) | 2011-02-07 |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (NCT01296035) | Women and Infants Hospital of Rhode Island | 2011-02-01 |
| Phase II ABT-888 With Cyclophosphamide (NCT01306032) | National Cancer Institute (NCI) | 2011-01-12 |
| Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive (NCT01262040) | Memorial Sloan Kettering Cancer Center | 2010-12-14 |
| A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer (NCT01281514) | Fox Chase Cancer Center | 2010-12-14 |
| Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer (NCT01248962) | Memorial Sloan Kettering Cancer Center | 2010-11-01 |
| Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer (NCT01253681) | Amgen | 2010-11-01 |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian (NCT01219777) | Ritu Salani | 2010-09-01 |
| Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (NCT01031381) | University of Pittsburgh | 2010-09-01 |
| Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer (NCT01216813) | Royal Marsden NHS Foundation Trust | 2010-08-01 |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer (NCT01188876) | Massachusetts General Hospital | 2010-08-01 |
| Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients (NCT01308944) | Washington University School of Medicine | 2010-08-01 |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (NCT01166737) | AGO Study Group | 2010-07-01 |
| Neoadjuvant Therapy for Ovarian Cancer (NCT01146795) | Jason D. Wright | 2010-05-17 |
| Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (NCT01506856) | Gynecologic Oncology Trial & Investigation Consortium | 2010-05-01 |
| Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer (NCT01091428) | Millennium Pharmaceuticals, Inc. | 2010-04-16 |
| Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer (NCT00993655) | Canadian Cancer Trials Group | 2010-03-03 |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor (NCT01096381) | Vanderbilt-Ingram Cancer Center | 2010-03-01 |
| A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT01570582) | Korean Gynecologic Oncology Group | 2010-03-01 |
| Irinotecan and Bevacizumab for Recurrent Ovarian Cancer (NCT01091259) | NYU Langone Health | 2010-03-01 |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00872989) | SWOG Cancer Research Network | 2010-03-01 |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies (NCT01065662) | Susana M. Campos, MD | 2010-02-01 |
| Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182 (NCT01074398) | Gynecologic Oncology Group | 2010-02-01 |
| Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction (NCT01083537) | University Health Network, Toronto | 2010-02-01 |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma (NCT01035658) | SCRI Development Innovations, LLC | 2010-01-01 |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616) | National Cancer Institute (NCI) | 2009-12-01 |
| Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT (NCT01276574) | Turku University Hospital | 2009-10-01 |
| Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer (NCT01170299) | Royal Marsden NHS Foundation Trust | 2009-10-01 |
| Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) (NCT00959582) | Merck Sharp & Dohme LLC | 2009-09-01 |
| Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases (NCT01048814) | Precision Therapeutics | 2009-08-01 |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT01100372) | Medical University Innsbruck | 2009-07-01 |
| Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer (NCT00910000) | Dana-Farber Cancer Institute | 2009-06-01 |
| Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies (NCT01079832) | Case Comprehensive Cancer Center | 2009-05-01 |
| First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (NCT01669226) | Shanghai Gynecologic Oncology Group | 2009-04-01 |
| Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life (NCT00870233) | Memorial Sloan Kettering Cancer Center | 2009-03-24 |
| Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer (NCT00866723) | Beth Israel Deaconess Medical Center | 2009-03-01 |
| Study of Paclitaxel in Patients With Ovarian Cancer (NCT00989131) | Oasmia Pharmaceutical AB | 2009-02-01 |
| Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer (NCT00850772) | Queensland Centre for Gynaecological Cancer | 2009-01-01 |
| AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (NCT00770536) | Amgen | 2009-01-01 |